Market News & Trends
BriaCell Announces Clinical Supply Agreement With BeiGene for Bria-OTS First in Human Study
BriaCell Therapeutics Corp. recently announced a clinical supply agreement with BeiGene, Ltd. to evaluate the safety and efficacy of Bria-OTS, BriaCell’s next generation immunotherapy, in…
Vetter Wins Best Managed Companies Award 2024
Vetter has once again been awarded the Best Managed Companies Award, marking its fifth consecutive win. The jury made its selection based on Vetter’s consistency…
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 in Patients With Alzheimer’s Disease
Coya Therapeutics, Inc. recently announced the completion of a randomized, double-blind, placebo-controlled Phase 2 study of LD IL-2 in patients with mild-to-moderate AD. The study…
Amphista Therapeutics Unveils New Differentiated Mechanism of Action for BRD9 Degradation
Amphista’s bifunctional BRD9 degraders selectively induce BRD9 to DCAF16 proximity and serve as molecular glues, leading to strong and rapid degradation of BRD9….
TFF Pharmaceuticals & Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program Into Preclinical Testing
TFF Pharmaceuticals, Inc. recently announced the government will be advancing several next-generation medical countermeasures (MCMs) formulated with its Thin Film Freezing technology into advanced preclinical…
Pneumagen Presents Positive Phase 2 Influenza Human Challenge Study Data
Pneumagen recently presented positive results from its Phase 2, proof-of-concept, Controlled Human Infection Model (CHIM) study in which healthy volunteers were challenged with influenza virus…
Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Launched In Japan
Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac group, recently announced they have launched the anti-rheumatic agent Metoject Subcutaneous Injection 7.5…
Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for Descartes-08 for the Treatment of Myasthenia Gravis
Cartesian Therapeutics, Inc. recently announced the US FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation for Descartes-08 for the treatment of myasthenia gravis (MG).…
Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid Tumors
Indaptus Therapeutics, Inc. recently announced the successful advancement of its Phase 1 trial for Decoy20, an investigational novel package of broad immune agonists for cancer…
First-In-Class Cholesterol-Lowering Treatment & its Combination With Ezetimibe Approved In Europe to Treat Hypercholesterolemia & Significantly Reduce Cardiovascular Risk
Daiichi Sankyo Europe GmbH and Esperion Therapeutics, Inc. jointly announced the European Commission (EC) has approved the label update of both NILEMDO (bempedoic acid) and…
AGC Biologics & BioConnection Partner to Offer New End-to-End Biopharmaceutical Drug Substance & Drug Product Development & Manufacturing Offering
AGC Biologics and BioConnection recently announced a new strategic partnership. The companies are partnering to provide end-to-end biopharmaceutical development and manufacturing capabilities for drug substance…
Asymchem Secures Former Pfizer Development & API Pilot Plant Manufacturing Facilities
Asymchem Laboratories (Tianjin) Co., Ltd. recently announced today it will operate the former Pfizer UK small molecule API pilot plant and part of the development…
Alvotech & Dr. Reddy’s Enter Commercialization Collaboration
Alvotech and Dr. Reddy’s Laboratories SA recently announced the companies have entered into a license and supply agreement for the commercialization of AVT03, Alvotech’s biosimilar candidate to….
Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
Lipella Pharmaceuticals Inc. recently announced the receipt of US FDA Type-C meeting guidance regarding the LP-10 (liposomal tacrolimus) clinical program. Lipella expects to initiate a…
Limula Raises $6.8M to Democratise Access to Life-Saving Cell & Gene Therapies With Swiss-Made Manufacturing Platform
Over the past decade, several breakthrough Cell and Gene Therapy products have been approved in the US and Europe to turn stem cells and immune…
Molecure Receives Approval to Initiate Phase 2 Clinical Trial for the Treatment of Pulmonary Sarcoidosis
Molecure S.A. recently announced it has received national regulatory approvals from Denmark, France, Greece, Germany, and Norway to conduct a Phase 2 clinical trial for…
Blue Mountain Appoints Chief Growth Officer to Spearhead Global Expansion & Strategic Partnerships in Life Sciences Sector
Blue Mountain, the leader in GMP-compliant EAM (Enterprise Asset Management) software for life sciences, proudly announces the appointment of Keith Pensabene as its first-ever Chief…
Sana Biotechnology Highlights Novel In Vivo Preclinical Data Showing Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington’s Disease and Other Glial-Based Neurodegenerative Conditions
Healthy transplanted human glial cells replaced diseased glial cells in the brains of human glial chimeric Huntingtin mice….
Premium Cell Culture Ingredients From Actylis
Download the Actylis Cell Culture Ingredients brochure to discover our product list or ask for a sample of a specific product…..
TFF Pharmaceuticals & Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical Testing
TFF Pharmaceuticals, Inc recently announced that, in collaboration with Cleveland Clinic, the company is advancing multiple multivalent universal influenza vaccines to protect against seasonal and…
